Encouraging preliminary results from a phase I clinical trial using anti-CD19/CD22 CAR-Ts were reported, with 8/11 B-ALL patients achieving CR without evidence of antigen-negative escape, despite the short follow up of 60 days [21]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.